BioWorld

Aug. 23, 2006

Shell Firm Acquiring Protalix, Phase III Gaucher's Therapy

Public shell company Orthodontix Inc. is gaining a Phase III-ready drug for Gaucher's disease along with a plant-cell bioreactor for making proteins in its merger with Israeli firm Protalix Ltd. (BioWorld Today) Read More

Belgian Firm Peakadilly Gets €14.5M In Series A

No Abstract Read More

Anthracycline Prodrug Added To Innovive's Cancer Pipeline

Thiakis Series A Brings In £10M For Obesity Program

Appointments And Advancements

Clinic Roundup

Other News To Note

Today's news in brief

BioWorld

BioWorld briefs for June 18, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for June 18, 2025.

An early stage 85% remissions rate in AML drives Aptevo’s stock surge

BioWorld

An 85% remissions rate was found in updated results from Aptevo Therapeutics Inc.’s ongoing phase Ib/II Ranier study of mipletamig in one of the toughest blood...

BIO 2025: Makary lays out FDA’s path, launches pilot review program

BioWorld

On the same day that FDA Commissioner Martin Makary spoke in a fireside chat during the 2025 Biotechnology Innovation Organization’s International Convention, the...

3D illustration of a chain of amino acid or biomolecules called protein

Alphadesign: AI creating proteins from scratch

BioWorld Science

The Alphafold machine learning system for predicting a protein’s structure from its amino acid sequence has been adapted to make it possible to design de novo...